Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$17,500.00

Defining the tumour-specific antigen landscape of lung cancer

EF 2018-19

Résumé
Cancer cells behave very differently from normal cells and employ multiple mechanisms to avoid recognition by the innate immune system. In addition to gain of function mutations that confer them a proliferative advantage, cancer cells also express non-coding variants that can disrupt chromatin structure and activate oncogenic transcription of proto-oncogenes. However, the search for tumour specific antigens (TSAs) presented by the major histocompatibility complex of cancer cells has produced less than a handful of putative candidates. This relatively meagre success is partly attributed to current search strategies that are often limited to the expression of source proteins originating from the canonical genome. Accordingly, we proposed here a novel proteogenomic approach that leverages high performance mass spectrometry and bioinformatics tools to uncover TSAs from coding and non-coding regions. We propose to apply this approach to the identification of TSAs from lung cancer, a leading cause of cancer-related deaths worldwide with 1.8 million people being diagnosed every year. Given that lung cancer mutates at a high rate, we expect that lung tumour cells will express many of these unique antigens. In this project, we will be sequencing the genome of 40 tumours from 4 different classes of lung cancer to search for these TSAs. Finally, we will be classifying these components into two groups based on how they originated. The findings of such research could contribute to the development of a vaccine that makes use of these cancer-specific components to prime the immune system to attack cancer cells.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
418303
Name
Cleyle Jenna
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Defining the tumour-specific antigen landscape of lung cancer
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antigen Recognition; Bioinformatics; Cancer Immunotherapy; Genomics; Major Histocompatibility Complex; Mass Spectrometry; Proteogenomics; T-Cell Responses
Abstract
Cancer cells behave very differently from normal cells and employ multiple mechanisms to avoid recognition by the innate immune system. In addition to gain of function mutations that confer them a proliferative advantage, cancer cells also express non-coding variants that can disrupt chromatin structure and activate oncogenic transcription of proto-oncogenes. However, the search for tumour specific antigens (TSAs) presented by the major histocompatibility complex of cancer cells has produced less than a handful of putative candidates. This relatively meagre success is partly attributed to current search strategies that are often limited to the expression of source proteins originating from the canonical genome. Accordingly, we proposed here a novel proteogenomic approach that leverages high performance mass spectrometry and bioinformatics tools to uncover TSAs from coding and non-coding regions. We propose to apply this approach to the identification of TSAs from lung cancer, a leading cause of cancer-related deaths worldwide with 1.8 million people being diagnosed every year. Given that lung cancer mutates at a high rate, we expect that lung tumour cells will express many of these unique antigens. In this project, we will be sequencing the genome of 40 tumours from 4 different classes of lung cancer to search for these TSAs. Finally, we will be classifying these components into two groups based on how they originated. The findings of such research could contribute to the development of a vaccine that makes use of these cancer-specific components to prime the immune system to attack cancer cells.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cleyle, Jenna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~